What NeuroDex does

NeuroDex is a private biotechnology company headquartered at 22 Strathmore Road, Natick, Massachusetts (founded circa 2019), that develops blood-based biomarker diagnostics and bioanalytical services for neurological disorders. The company operates Neurodex Laboratories, a GLP-compliant and CLIA-certified facility, and serves pharmaceutical and biotechnology sponsors developing therapeutics for Alzheimer's, Parkinson's, ALS, FTD, and other neurodegenerative conditions, as well as academic medical centers and disease foundations funding translational neuroscience research.

The company's core technology is the ExoSort Platform, a proprietary immunoaffinity isolation system that selectively isolates neuron-derived extracellular vesicles (NDEs) from plasma. This enables brain-specific biomarker analysis from a simple blood draw rather than lumbar puncture, and runs in an automated 96-well plate format with low within- and between-batch variability. Building on ExoSort, the Neurodiagnostic Platform offers validated biomarker panels — α-Syn (Parkinson's, MSA, Alzheimer's), TDP43 (ALS, FTD, Alzheimer's), Tau/pTau (Alzheimer's), NF-L (brain injury, neuroinflammation), LC3 (autophagy), NF-kB (neuroinflammation), AKT (metabolic), and synaptic proteins — used for pharmacodynamic monitoring, patient stratification, and endpoint analysis. The company has also developed an Alpha-Synuclein Seed Amplification Assay (αSyn-SAA) using RT-QuIC technology for early Parkinson's detection.

NeuroDex operates a project-based, sales-led B2B business model with quote-based, non-public pricing. Revenue is generated through four streams: biomarker discovery services (immunoassay- and RNA-seq-based), translational research collaborations with pharma and biotech, clinical trial biomarker support for Phase I–III studies, and Research Use Only consumables (plates, assays, reagents). Customer and partner logos include Alkermes, QurAlis, NeuroSense, SBH Science, Yale University, Stanford University, Johns Hopkins University, Massachusetts General Hospital, Trieste University, the Michael J. Fox Foundation, the Alzheimer's Drug Discovery Foundation, and the NIH. Scientific credibility is reinforced through peer-reviewed publications (notably in the Journal of Extracellular Biology) and participation in industry conferences including AAIC 2024.

Name

NeuroDex

Legal name

NeuroDex Inc.

Website

https://neurodex.co

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

NeuroDex is a Natick, Massachusetts-based biotechnology company developing blood-based neuron-derived extracellular vesicle (NDE) biomarker diagnostics and bioanalytical services for pharmaceutical, biotech, and academic clients working on Alzheimer's, Parkinson's, ALS, and other neurological disease therapeutics.

Ownership category

akta.pro rank

Product category

Neurological Biomarker Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD)

Keywords

• Neurological biomarker discovery
• Extracellular vesicle isolation
• Neurodegenerative disease diagnostics
• Clinical trial biomarker services
• Precision neurology platforms

Headquarters

HQ city

Natick

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biomarker Discovery Services: Leverage brain-enriched exosomes to discover novel biomarkers for neurological diseases using immunoassays and RNA sequencing. Project-based research collaborations with pharmaceutical and biotech companies.
2. Translational Research Biomarkers: Partnering with pharmaceutical and biotechnology companies to translate NDE biomarkers into clinically relevant endpoints for drug development. Collaborative development arrangements.
3. Clinical Trial Biomarker Support: Biomarker services tailored for integration into Phase I–III clinical trials including stratification, pharmacodynamic monitoring, and endpoint analysis. Contract-based service revenue.
4. Neurodiagnostic Platform Products: Sale of biomarker assay plates, assays, and reagents (consumables) for neurological disease detection and monitoring. Products sold under research use only terms.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

NeuroDex develops and delivers biomarker discovery, translational research, and clinical trial support services built on its proprietary ExoSort Platform for isolating neuron-derived extracellular vesicles (NDEs) from blood samples. The company sells biomarker assay plates, assays, and reagents as research-use-only products and provides end-to-end biomarker solutions for pharmaceutical, biotechnology, and academic clients targeting Parkinson's, Alzheimer's, ALS, and neuroinflammatory diseases.

Product overview

NeuroDex is a biotechnology company offering a unified platform centered on the ExoSort Platform for isolating neuron-derived extracellular vesicles (NDEs) and the Neurodiagnostic Platform featuring multiple validated biomarker panels (α-Syn, TDP43, Tau/pTau, NF-L, LC3, NF-kB, AKT, Synaptic Protein). The portfolio includes complementary laboratory services provided through Neurodex Laboratories (GLP/CLIA compliant), Biomarker Discovery Services, Translational Research Biomarkers, Pre-Clinical Research Services, and Clinical Trial Services. These offerings work together to provide end-to-end biomarker solutions from discovery through clinical validation for neurological disorders including Parkinson's, ALS, Alzheimer's, and neuroinflammatory diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• ExoSort Platform Proprietary immunoaffinity isolation platform for capturing neuron-derived extracellular vesicles (NDEs) from blood samples, enabling brain-specific biomarker analysis from plasma without invasive procedures. Offered to pharmaceutical, biotechnology, and academic customers for neurological disease research.
• Neurodiagnostic Platform A biomarker platform featuring validated panels including α-Syn (Parkinson's, MSA, Alzheimer's), TDP43 (ALS, FTD), Tau/pTau (Alzheimer's), NF-L (brain injury, neuroinflammation), LC3 (autophagy/lysosome), NF-kB (neuroinflammation), AKT panel (metabolic changes), and Synaptic Protein (synaptic plasticity) for monitoring disease progression and treatment response.
• Neurodex Laboratories GLP-compliant and CLIA-certified laboratory providing biomarker analysis services, with full assay validation expected Q2 2026. Services span biomarker discovery, translational research, and clinical trial support.
• Biomarker Discovery Services Leverages brain-enriched exosomes to discover novel biomarkers for neurological diseases using immunoassays and RNA sequencing. Project-based research collaborations with pharmaceutical and biotechnology companies.
• Clinical Trial Services Biomarker services tailored for integration into Phase I–III clinical trials, including patient stratification, pharmacodynamic monitoring, and endpoint analysis. Offered to pharmaceutical and biotechnology sponsors.
• Pre-Clinical Research Services Pre-clinical biomarker services supporting drug development studies prior to human trials. Offered to pharmaceutical and biotechnology companies advancing neurological disease therapeutics.
• Alpha-Synuclein Seed Amplification Assay (αSyn-SAA) Diagnostic technology using RT-QuIC (Real-Time Quaking-Induced Conversion) to detect pathological, seeding-competent forms of alpha-synuclein for early Parkinson's disease detection and clinical trial stratification, achieving over 90% sensitivity and specificity for prodromal Parkinson's pathology.

Quantifiable outcome

• Over 90% sensitivity and specificity for α-syn-SAA detection of Parkinson's pathology in prodromal stages
• +2 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Stanford UniversitycoreStrategic or Co-development PartnerResearch collaboration on CNS target engagement studies. Published first evidence of CNS target engagement for GLP-1 and PPARγ agonists using blood-based neuron-derived extracellular vesicles. Multi-institution research partnership advancing neurological biomarker science.
• Yale UniversitycoreStrategic or Co-development PartnerAcademic research partnership in biomarker discovery and validation. Collaborates on neurological disease research leveraging NeuroDex's NDE isolation technology.
• Massachusetts General HospitalcoreStrategic or Co-development PartnerResearch collaboration with MGH Biomarker Discovery Lab on tissue samples and biomarker validation for neurological disease research.
• Johns Hopkins UniversitycoreStrategic or Co-development PartnerAcademic research partnership for biomarker discovery and validation in neurological disorders.
• QurAlisminorStrategic or Co-development PartnerBiotechnology company partnership for ALS and neurological disease biomarker research collaboration.
• NeuroSenseminorStrategic or Co-development PartnerBiotechnology company partnership for neurological biomarker research and development.
• AlkermescoreStrategic or Co-development PartnerPharmaceutical company partnership for translational research biomarkers and drug development endpoint validation.
• SBH ScienceminorStrategic or Co-development PartnerScientific research collaboration in biomarker discovery services.
• Target ALScoreStrategic or Co-development PartnerAwarded Target ALS Biomarker Consortia Grant in 2024 to develop ALS biomarker by analyzing neuron-derived extracellular vesicles. Goal is minimally invasive method to monitor ALS progression and treatment response.
• Michael J. Fox FoundationcoreStrategic or Co-development PartnerNon-profit research foundation partnership for Parkinson's disease biomarker research and funding.
• Alzheimer's Drug Discovery FoundationcoreStrategic or Co-development PartnerNon-profit foundation partnership for Alzheimer's disease biomarker research and drug discovery funding.
• NIHcoreStrategic or Co-development PartnerGovernment research funding agency partnership for neurological disease research funding and collaboration.
• Trieste UniversityminorStrategic or Co-development PartnerInternational academic partnership for neurological biomarker research collaboration.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Evelo Biosciences: Although primarily inflammation-focused, Evelo represents the broader class of emerging biomarker-driven biotechs that compete for the same pharma partnership and grant funding pool as NeuroDex.
• Alamar Biosciences: Ultra-sensitive proteomics platform (NULISA) targeting neurology and inflammation biomarkers. Emerging alternative to NDE-based approaches for CNS biomarker measurement in clinical trials.

Direct peers

• ADx NeuroSciences: Specialized biomarker assay developer focused on neurodegenerative disease diagnostics (Alzheimer's, Parkinson's). Provides complementary and competing immunoassays for CNS drug development.
• Quanterix: Simoa ultra-sensitive immunoassay platform widely used for neurology biomarker detection (NfL, p-Tau). Provides competing biomarker measurement technology serving overlapping pharma and academic customers.
• C2N Diagnostics: Commercial-stage blood-based diagnostics for Alzheimer's disease (PrecivityAD) with CLIA-certified lab. Competes for pharma AD trial stratification contracts and shares NeuroDex's neurology biomarker services model.
• Amprion: Develops Seed Amplification Assays (SAA/RT-QuIC) for synucleinopathies including Parkinson's and MSA. Directly comparable to NeuroDex's αSyn-SAA diagnostic offering and competes for the same clinical trial biomarker opportunities.

Others

• Simoa Neurology Biomarker Consortia (academic core labs e.g., Sahlgrenska, ADNI): Academic biomarker core labs running in-house immunoassays for pharma-sponsored studies. They compete indirectly for translational research budgets and provide a benchmark for in-sourcing vs. outsourcing biomarker work.

Broad incumbents

• Bio-Techne: Large life sciences tools company with extensive neuroscience biomarker reagents, ELISA kits, and proteomics platforms. Competes across NeuroDex's RUO consumables business and serves overlapping pharma/academic customers.
• Fujirebio: Major clinical diagnostics company with established neurology biomarker menu including CSF assays for AD. Represents a potential IVD partner or competitive incumbent in regulated CNS diagnostics.
• Roche Diagnostics: Global diagnostics leader with Elecsys neurology biomarker assays (p-Tau181, NfL, GFAP) deployed on widespread clinical instrumentation. Sets pricing and standards in the CNS IVD market NeuroDex aspires to enter.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroDex